Fisher Asset Management LLC Boosts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Posted by Defense World Staff on Apr 29th, 2023

Fisher Asset Management LLC lifted its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) by 31.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,792 shares of the biopharmaceutical company’s stock after purchasing an additional 32,136 shares during the quarter. Fisher Asset Management LLC owned 0.24% of Vanda Pharmaceuticals worth $996,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. State Street Corp increased its holdings in Vanda Pharmaceuticals by 22.1% in the 1st quarter. State Street Corp now owns 4,063,298 shares of the biopharmaceutical company’s stock worth $45,956,000 after buying an additional 735,865 shares in the last quarter. Millennium Management LLC increased its holdings in Vanda Pharmaceuticals by 42.7% in the 2nd quarter. Millennium Management LLC now owns 1,190,410 shares of the biopharmaceutical company’s stock worth $12,975,000 after buying an additional 356,418 shares in the last quarter. Foundry Partners LLC bought a new stake in Vanda Pharmaceuticals in the 4th quarter worth about $2,086,000. Dimensional Fund Advisors LP increased its holdings in Vanda Pharmaceuticals by 11.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,263,159 shares of the biopharmaceutical company’s stock worth $25,597,000 after buying an additional 229,581 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in Vanda Pharmaceuticals by 6,778.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 191,964 shares of the biopharmaceutical company’s stock worth $1,896,000 after buying an additional 189,173 shares in the last quarter. Hedge funds and other institutional investors own 97.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Vanda Pharmaceuticals in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company.

Vanda Pharmaceuticals Stock Performance

NASDAQ VNDA opened at $6.14 on Friday. Vanda Pharmaceuticals Inc. has a one year low of $6.05 and a one year high of $11.90. The stock has a 50-day moving average of $6.53 and a 200 day moving average of $8.05. The company has a market capitalization of $352.68 million, a price-to-earnings ratio of 51.17 and a beta of 0.71.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) last released its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The business had revenue of $64.48 million during the quarter, compared to the consensus estimate of $67.60 million. Vanda Pharmaceuticals had a return on equity of 1.22% and a net margin of 2.47%. On average, equities analysts predict that Vanda Pharmaceuticals Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, SVP Timothy Williams sold 8,437 shares of the business’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.24, for a total transaction of $52,646.88. Following the completion of the sale, the senior vice president now directly owns 111,814 shares in the company, valued at approximately $697,719.36. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Vanda Pharmaceuticals news, SVP Timothy Williams sold 8,437 shares of the business’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $6.24, for a total transaction of $52,646.88. Following the completion of the sale, the senior vice president now directly owns 111,814 shares in the company, valued at approximately $697,719.36. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Mihael Hristos Polymeropoulos sold 22,426 shares of the business’s stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $6.23, for a total value of $139,713.98. Following the sale, the chief executive officer now owns 1,499,440 shares of the company’s stock, valued at $9,341,511.20. The disclosure for this sale can be found here. Insiders sold a total of 46,549 shares of company stock worth $290,324 in the last three months. 7.00% of the stock is currently owned by company insiders.

About Vanda Pharmaceuticals

(Get Rating)

Vanda Pharmaceuticals, Inc engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.